Lexicon Pharmaceuticals

Focus: Lexicon Pharmaceuticals is a small-molecule and biologics-focused pharma company headquartered in Bridgewater, NJ, with a primary marketed asset (INPEFA) in metabolic and cardiovascular indications.

Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Lexicon Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Lexicon Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

1 in 5yr

INPEFA

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

INPEFA

Type 2 Diabetes Mellitus, Heart Failure

$659K Part D

Growth

Help build intelligence for Lexicon Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Single blockbuster asset (INPEFA) generating revenue across Type 2 Diabetes and Heart Failure with growth-phase lifecycle potential through 2030
Diversified pipeline spanning 20+ active programs across metabolic, neurological, and gastrointestinal indications provides exposure to multiple therapeutic areas
Sotagliflozin platform being explored across 6+ indications (Type 1/2 Diabetes, Heart Failure, Hypertrophic Cardiomyopathy) suggests significant upside potential if additional approvals achieved

Watch Out For

100% revenue concentration in single product (INPEFA) creates existential business risk; patent cliff at October 2030 threatens entire revenue base with only $659K Part D spending suggesting limited market penetration
Pipeline heavily skewed toward early-stage (13 Phase 1 programs) with only 1 Phase 3 active, indicating 5-7+ year wait for next meaningful catalysts and limited near-term revenue diversification

Pipeline & Clinical Trials

telotristat ethyl

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT04034745Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

N/A

LX4211

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01555008Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Phase 1

Sotagliflozin

Platelet Function and Reactivity Tests

Phase 1

Clinical Trials (1)

NCT06933056Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Phase 1

sotagliflozin

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT02471274PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Phase 1

250 mg capsule

Irritable Bowel Syndrome

Phase 1

Clinical Trials (1)

NCT01411800An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Phase 1

Telotristat etiprate

Healthy

Phase 1

Clinical Trials (1)

NCT02157584An Open-Label Food Effect Study of Telotristat Etiprate

Phase 1

Treatment A digoxin

Healthy

Phase 1

Clinical Trials (1)

NCT02300350DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Phase 1

Telotristat etiprate

Drug Interactions

Phase 1

Clinical Trials (1)

NCT02147808A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

Phase 1

400 mg LX4211

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01292993A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Phase 1

Telotristat etiprate

Drug Interactions

Phase 1

Clinical Trials (1)

NCT02195635Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Phase 1

LX4211

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01441232A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Phase 1

Omeprazole 40 MG

Drug-drug Interaction

Phase 1

Clinical Trials (1)

NCT03302845A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

Phase 1

Sotagliflozin

Renal Impairment

Phase 1

Clinical Trials (1)

NCT02647918Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Phase 1

Telotristat Ethyl

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT03423446Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Phase 1

Schedule A

Healthy

Phase 1

Clinical Trials (1)

NCT01334242A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Phase 1

Telotristat etiprate

QT Interval

Phase 1

Clinical Trials (1)

NCT02155205A Thorough QT Study of Telotristat Etiprate

Phase 1

LX4211 400 mg

Healthy

Phase 1

Clinical Trials (1)

NCT01916850Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Phase 1

50 mg LX3305 QD

Rheumatoid Arthritis

Phase 1

Clinical Trials (1)

NCT01417052A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Phase 1

300 mg LX4211

Type 2 Diabetes Mellitus

Phase 1

Clinical Trials (1)

NCT01188863Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Phase 1

LX4211 800 mg

Healthy

Phase 1

Clinical Trials (1)

NCT01913002Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Phase 1

sotagliflozin

Healthy

Phase 1

Clinical Trials (1)

NCT02494609Oral Contraceptive DDI Study

Phase 1

Treatment A

Healthy

Phase 1

Clinical Trials (1)

NCT02300363DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Phase 1

[14C]-LX4211

Healthy

Phase 1

Clinical Trials (1)

NCT01818232Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

Phase 1

LX3305

Rheumatoid Arthritis

Phase 1

Clinical Trials (1)

NCT00847886Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Phase 1

LX4211 400 mg

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT01916863Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Phase 1

Fexofenadine

Drug Interactions

Phase 1

Clinical Trials (1)

NCT02157558An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Phase 1

500 mg [14C]-LX1606

Carcinoid Syndrome

Phase 1

Clinical Trials (1)

NCT01932528An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

Phase 1

LX4211

Healthy

Phase 1

Clinical Trials (1)

NCT02373046Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Phase 1

LX7101

Primary Open-angle Glaucoma

Phase 1/2

Clinical Trials (1)

NCT01528111Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 1/2

Sotagliflozin

Type 1 Diabetes

Phase 1/2

Clinical Trials (1)

NCT05696366Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

Phase 1/2

Placebo

Type 1 Diabetes Mellitus

Phase 2

Gemcitabine

Locally Advanced Unresectable Pancreatic Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT03910387Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Phase 2

Sotagliflozin

Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT06435156Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Phase 2

Sotagliflozin

Cardiac Failure Aggravated

Phase 2

LX1031 High Dose

Irritable Bowel Syndrome

Phase 2

Clinical Trials (1)

NCT00813098Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Phase 2

Placebo

Postherpetic Neuralgia

Phase 2

Clinical Trials (1)

NCT04662281Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

Phase 2

75 mg LX4211

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT01376557Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Phase 2

Telotristat etiprate

Carcinoid Syndrome

Phase 2

Clinical Trials (1)

NCT01104415Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Phase 2

Sotagliflozin

Type 1 Diabetes Mellitus

Phase 2

LX9211

Diabetic Peripheral Neuropathy

Phase 2

Clinical Trials (1)

NCT04455633Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

Phase 2

Placebo

Diabetic Peripheral Neuropathic Pain

Phase 2

Clinical Trials (1)

NCT06203002A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 2

LX4211 Low Dose

Type 2 Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT00962065Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Phase 2

Sotagliflozin

Type 1 Diabetes Mellitus

Phase 2

250 mg LX1033 tablets

Irritable Bowel Syndrome

Phase 2

Clinical Trials (1)

NCT01494233A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Phase 2

Telotristat Etiprate

Ulcerative Colitis

Phase 2

Clinical Trials (1)

NCT01456052A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Phase 2

LX3305 low dose

Rheumatoid Arthritis

Phase 2

Clinical Trials (1)

NCT00903383Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Phase 2

Telotristat etiprate

Carcinoid Syndrome

Phase 2

Clinical Trials (1)

NCT00853047Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Phase 2

LX6171 High Dose

Age-Related Memory Disorders

Phase 2

Clinical Trials (1)

NCT00691808Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

Phase 2

Sotagliflozin

Type 2 Diabetes Mellitus

Phase 3

Sotagliflozin

Heart Failure

Phase 3

Interview Prep Quick Facts

Portfolio: 1 approved product, 48 clinical trials

Top TAs: Metabolic Diseases, Gastroenterology, Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Growth1 (100%)

1 total products

Therapeutic Area Focus

1 marketed9 pipeline

5 pipeline

1 marketed3 pipeline

4 pipeline

1 marketed2 pipeline

Lexicon Pharmaceuticals

About Lexicon Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (0)